Zactima™ Active in Advanced Non–Small Cell Lung Cancer
May 21st, 2009
Researchers involved in an International randomized Phase II clinical trial have shown that Zactima™ (vandetanib) may be more effective than Iressa® (gefitinib) for second-line therapy of patients with locally advanced or metastatic non–small cell lung cancer (NSCLC). The details of this study appeared in the May 20, 2009 issue of the Journal of Clinical Oncology.